August 15, 2012New England Journal of Medicine4,630 citationsOpen Access
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIRM ClinicalTrials.gov number, NCT00974311.).